Business Summary: Bioton SA is a Poland-based company active in the pharmaceutical sector. The Company is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The Company's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.
Financial Summary: BRIEF: For the three months ended 31 March 2026, BIOTON SA revenues decreased 25% to PLN49.1M. Net loss decreased 11% to PLN5.2M. Revenues reflect International markets - Direct segment decrease of 69% to PLN12M, International sales - SciGen segment decrease of 17% to PLN64M, Malaysia (Country) segment decrease of 86% to PLN4.7M. Lower net loss reflects Other segment income increase of 59% to PLN8.4M.